Compare ASRT & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASRT | MYO |
|---|---|---|
| Founded | 1995 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.1M | 33.2M |
| IPO Year | 1997 | 2017 |
| Metric | ASRT | MYO |
|---|---|---|
| Price | $0.76 | $1.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.00 | ★ $7.67 |
| AVG Volume (30 Days) | 438.8K | ★ 802.4K |
| Earning Date | 11-10-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $137,354,000.00 | $41,643,203.00 |
| Revenue This Year | N/A | $24.07 |
| Revenue Next Year | N/A | $17.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 9.22 | ★ 65.00 |
| 52 Week Low | $0.51 | $0.71 |
| 52 Week High | $1.01 | $7.17 |
| Indicator | ASRT | MYO |
|---|---|---|
| Relative Strength Index (RSI) | 47.26 | 61.37 |
| Support Level | $0.75 | $1.02 |
| Resistance Level | $0.80 | $1.13 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 74.57 | 77.35 |
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).